We are live on ! Find out more
ALZN icon

Alzamend Neuro
ALZN

12 hedge funds and large institutions have $122K invested in Alzamend Neuro in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

3.43% less ownership

Funds ownership: 6.46% → 3.04% (-3.4%)

8% less funds holding

Funds holding: 13 → 12 (-1)

73% less capital invested

Capital invested by funds: $447K → $122K (-$325K)

Holders
12
Holders Change
-1
Holders Change %
-7.69%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$36.3K
2
Citigroup
Citigroup
New York
+$10.4K
3
TRCT
Tower Research Capital (TRC)
New York
+$8.2K
4
CIAM
Caitong International Asset Management
Hong Kong
+$8

Top Sellers

Rank Fund Capital Flow
1
DS
DRW Securities
Illinois
-$212K
2
UBS Group
UBS Group
Switzerland
-$40.1K
3
VF
Virtu Financial
New York
-$23K
4
XT
XTX Topco
Cayman Islands
-$22.7K
5
Bank of America
Bank of America
North Carolina
-$78
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
1
Geode Capital Management
Massachusetts
$48.4K +$36.3K +18,174 +66%
VFT
2
Vanguard Fiduciary Trust
Pennsylvania
$22.3K +$42K +21,020 New
Morgan Stanley
3
Morgan Stanley
New York
$19.1K – – –
CA
4
Clearstead Advisors
Ohio
$10.6K – – –
TRCT
5
Tower Research Capital (TRC)
New York
$6.55K +$8.2K +4,103 +197%
Citigroup
6
Citigroup
New York
$5.54K +$10.4K +5,231 New
UBS Group
7
UBS Group
Switzerland
$4.77K -$40.1K -20,063 -82%
VCM
8
Vanguard Capital Management
Pennsylvania
$4.66K +$8.79K +4,400 New
BlackRock
9
BlackRock
New York
$463 – – –
SS
10
SBI Securities
Japan
$23 – – –
CIAM
11
Caitong International Asset Management
Hong Kong
$4 +$8 +4 New
HIA
12
Harbor Investment Advisory
Maryland
$1 – – –
DS
13
DRW Securities
Illinois
– -$212K -116,319 Closed
VF
14
Virtu Financial
New York
– -$23K -12,582 Closed
XT
15
XTX Topco
Cayman Islands
– -$22.7K -12,470 Closed
Bank of America
16
Bank of America
North Carolina
– -$78 -43 Closed

ALZN Hedge Fund Activity: Q1 2026 in Review

12 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q1 2026, worth a combined $122K — down 73% from $447K a quarter earlier.

Fund positioning in ALZN was balanced in Q1 2026: 4 funds opened new positions, 4 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $36.3K. The largest seller was DRW Securities, exiting entirely with an estimated $212K sold.

  • 12 institutional investors held Alzamend Neuro (ALZN) as of Q1 2026, down from 13 in Q4 2025.
  • Funds reported $122K of Alzamend Neuro stock for Q1 2026, down 73% quarter-over-quarter.
  • 4 funds opened new Alzamend Neuro positions in Q1 2026 and 4 closed out, a net change of 0 holders.
  • The largest Alzamend Neuro buyer in Q1 2026 was Geode Capital Management, an estimated $36.3K added.
  • The largest Alzamend Neuro seller in Q1 2026 was DRW Securities, an estimated $212K sold.

Based on aggregated 13F filings for Q1 2026.